The Peptide Wiki
Mapping Knowledge.
Advancing Discovery.
📩 Subscribe
// STATE LEGISLATION TRACKER

Arkansas SB 464: TO ENSURE THE CONFIDENTIALITY OF CERTAIN PROCEDURES INVOLVED IN THE EXECUTION OF A PERSON FOR A CAPITAL OFFENSE.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Signed
State
Arkansas
Bill
SB 464
Filed
2019-03-04
Read the bill
OpenStates →
Last reviewed
2026-10-02

Plain-English Summary

Arkansas SB464 is about keeping information confidential around execution procedures and lethal-injection supplies for capital punishment. Based on the title and available status, it does not regulate compounded peptides, off-label prescribing, telehealth, naturopathic or NP scope, FDA 503A/503B compounding, controlled substances prescribing, or prescription monitoring for peptide users.

Key Points

  • No direct peptide access impact
  • Does not change clinician prescribing scope
  • Does not address telehealth peptide care
  • Does not regulate 503A or 503B compounding
  • Focused on execution drug confidentiality

What to Watch For

i
Note The bill concerns lethal-injection drug sourcing, not patient access to compounded peptides.
i
Note Any compounding language appears tied to execution drugs, not ordinary medical compounding.
i
Note No apparent change to controlled-substance monitoring or peptide prescribing rules.

Where the Bill Stands

SB464 became Arkansas Act 810, with an act date of April 9, 2019.
· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.
Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws